Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 6/20 | 0.79 |
| ▸ | PRKCG | P05129 | 6/20 | 0.78 |
| ▸ | PRKCB | P05771 | 5/20 | 0.78 |
| ▸ | PRKCH | P24723 | 5/20 | 0.78 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.78 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.78 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.78 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.78 |
| ▸ | PRKCI | P41743 | 4/20 | 0.78 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.78 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.78 |
| ▸ | USP2 | O75604 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 2/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16922839 | 1.00 | PRKCA (0.79) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL312634 | 1.00 | PRKCA (0.79) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL18627982 | 1.00 | PRKCA (0.79) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL8192421 | 1.00 | PRKCA (0.79) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL22171801 | 1.00 | PRKCA (0.79) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL21578359 | 1.00 | PRKCA (0.79) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL2127254 | 1.00 | PRKCA (0.79) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL18210530 | 1.00 | PRKCA (0.79) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL892726 | 1.00 | PRKCA (0.79) | PRKCAPRKCGPRKCBPRKCHPRKCE | |
| SCHEMBL18210529 | 0.99 | PRKCA (0.81) | PRKCAPRKCGPRKCBPRKCHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806714-B2 | Compositions and methods of use of phorbol esters in the treatment of neoplasms | BIOSUCCESS BIOTECH CO., LTD. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190216763-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS IN THE TREATMENT OF NEOPLASMS | BIOSUCCESS BIOTECH CO. LTD. (US) | 2019-07-18 | — | — | US | disclosed |
| US-20150197478-A1 | Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke | CHANG RICHARD L (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197478-A1 | Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke | CHANG RICHARD L (US) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197478-A1 | Compositions And Methods Of Use Of Phorbol Esters For Treatment of Stroke | PMAIP1, PLAT, EBP | PRKCA 15/4885PRKCG 24/4885PRKCB 44/4885 |
| US-10806714-B2 | Compositions and methods of use of phorbol esters in the treatment of neoplasms | PMAIP1, MYD88, HRAS | PRKCA 15/4885PRKCG 33/4885PRKCB 26/4885 |
| US-20190216763-A1 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS IN THE TREATMENT OF NEOPLASMS | PMAIP1, MYD88, HRAS | PRKCA 15/4885PRKCG 33/4885PRKCB 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.